Garfield Alastair's Form 4 filing
Rhythm Pharmaceuticals, Inc. (RYTM) · filed Jul 2, 2026
- Accession no.
- 0001104659-26-080397
- Filed
- Jul 2, 2026, 4:52 PM ET
- Trade date
- Jul 1, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Garfield AlastairCIK 0002027261 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | MOption exerciseAcquired | +4,445 | – | – | 12,208 | Direct | |
| Jul 1, 2026 | Common Stock | FTax withholdingDisposed | −2,150 | $110.41 | −$237,381.5 | 10,058 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | MOption exerciseDisposed | −4,445 | $0.00 | $0 | 8,888 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.